STOCKHOLM, May 30, 2017 /PRNewswire/ --
Medivir AB (Nasdaq Stockholm: MVIR) today announces that Ola Burmark, Chief Financial Officer at Medivir will be leaving his position. He will continue to fulfill his duties until end of August. A recruitment process has begun to find his replacement.
“Medivir has transformed into an oncology-focused research and development company with a broad pipeline of attractive projects. Ola has been an instrumental part of the executive leadership team in creating the new company and I want to thank him for his contributions and wish him good luck in his future career,” says Christine Lind, CEO of Medivir.
“I have had a rewarding and instructive time at Medivir and the privilege to be involved in the most intense years of the company’s changes. Medivir is on a new journey with a vision to improve life for cancer patients through the development of transformative drugs and thus this is a good time to transition”, says Ola Burmark.
A recruitment firm has been retained and the process of finding a successor has started.
For further information, please contact:
Christine Lind,
CEO Medivir AB,
Mobile +46 (0) 72-704-3211
About Medivir
Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List.
This information was brought to you by Cision http://news.cision.com
http://news.cision.com/medivir/r/medivir-s-cfo-will-leave-his-position---successor-recruitment-underway,c2275672
The following files are available for download:
Press release (PDF) |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/medivirs-cfo-will-leave-his-position---successor-recruitment-underway-300465213.html
SOURCE Medivir
